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Abstract 
Purpose: To investigate if ellagic acid exerts neuroprotective effects in hypoxic-ischemic (HI) brain 
injury by inhibiting apoptosis and inflammatory responses.  
Methods: Separate groups of rat pups from post-natal day 4 (D4) were administered with ellagic acid 
(10, 20 or 40 mg/kg body weight) orally till post-natal day 10 (D10). On D10, the rats were subjected to 
HI brain injury. Following HI injury, infarct size, weight and volume of the brain were measured. 
Apoptosis was assessed by Fluoro-Jade C staining. Expression of caspases (caspase-3, 8 and 9), 
apoptotic pathway proteins (Bax, Bad, Bcl-2 and Bcl-xL), MAPKs, NF-κB(p65) and p-IK-Bα were 
assessed by western blotting. mRNA levels of inflammatory mediators (TNF-α, IL-1α, IL-1β, iNOS, 
COX-2) were analyzed.  
Results: Ellagic acidmarkedly (p < 0.05) reduced infarct size, volume and tissue loss. Significant (p < 
0.05) reduction in neuroapoptosis was observed on pre-treatment with ellagic acid. Expression levels of 
caspases, apoptotic pathway proteins and MAPK proteins were down-regulated with marked (p < 0.05) 
suppression of inflammatory mediators, NF-κB(p65) and p-IK-Bα.  
Conclusion: Ellagic acid affords neuroprotection in HI brain injury by inhibiting apoptosis, inflammatory 
responses and modulating the proteins of apoptotic and MAPK pathways. Thus, ellagic acid may be a 
potent candidate for the treatment of HI injury. 
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Neonatal hypoxic-ischemic (HI) brain injury is a 
major cause of perinatal mortality and morbidity 
[1]. Perinatal HI has an incidence rate of 18 
cases in every 1000 births, affecting 
approximately 60 % of pre-term infants [2]. HI 
brain injury arising in neonatal and perinatal 
stages damages brain cell development, 
resulting in long-lasting neurologic sequelae with 
cerebral palsy, epilepsy, learning disabilities and 
motor disability as complications [3]. Brain injury 
in perinatal stage has multifaceted aetiology 
involving inflammation, a major cause in the 
progression of HI-induced injury in neonates and 
in adults [4]. Inflammation is involved in 
sensitizing the neonatal brain to ischaemia 
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through pro-inflammatory cytokines which are 
found in increased levels [5].  
 
Mitogen activated protein kinases (MAPKs) - 
p38s, extracellular signal-regulated kinases 
(ERKs) and c-Jun NH2-terminal kinases (JNKs) 
are activated in mammalian cells in response to 
various growth factors, cytokines and agents that 
cause cell damage [6]. The activated MAPKs 
principally function as mediators of cellular stress 
by phosphorylating various transcription factors, 
cytosolic proteins and intracellular enzymes that 
are chiefly involved in cell survival, apoptosis and 
in expression of inflammatory mediators [7]. 
 
Recently much of research work is focusing on 
plant-derived compounds for their 
neuroprotective effects. Ellagic acid is found in 
numerous plants, predominantly in fruits and nuts 
such as cranberries, pomegranates, raspberry, 
strawberries and walnuts [8]. Previous 
researchers have reported that ellagic acid 
possesses various pharmacological properties 
through regulation of several pathways such as 
glycogen synthase kinase-3 beta (GSK-3β)/ 
phosphoinositide 3-kinase (PI3-K) signaling [9]; 
regulation of cytokines [10]; activating antioxidant 
response [11]; and modulating the cell-cycle/cell 
survival genes [12]. Considering these biological 
effects the present study aimed to explore the 





Chemicals and reagents 
 
Ellagic acid was purchased from Sigma-Aldrich, 
St.Louis, MO, USA. Antibodies against caspase-
3, caspase-8, caspase-9, Bcl-xL, Bcl-2, Bax, Bad 
(Cell Signalling Technology, Danvers, MA, USA). 
β-actin, JNK, phospho-JNK, ERK1/2, phospho-
ERK1/2, p38, phospho-p38, NF-κB(p65), p-IKBα 
(Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) were used in expression analysis. All other 
chemicals and reagents were obtained from 
Sigma-Aldrich, St.Louis, MO, USA, unless 




Pregnant Sprague Dawley rats (Guangdong 
Medical Laboratory Animal Co., China) used in 
this study was maintained on 12 h light/dark 
cycle with room temperature at 22 ± 1 °C. The 
rats had ad libitum access to water and feed and 
were housed individually in separate cages and 
monitored closely for the day of litter of pups. 
The day of litter was noted as postnatal day 0 
(Day0). The pups were kept in cages with their 
littermates in conditions similar to their dams. 
From day 4, separate groups of pups were 
administered with ellagic acid (10, 20 or 40 
mg/kg b.wt, orally). On D10, one hour after 
treatment with ellagic acid, the pups were 
experimentally subjected to HI. Pups not treated 
with ellagic acid and not subjected to HI served 
as control, while pups exposed to HI injury and 
not treated with ellagic acid served as the HI 
control. For animal studies, ethical approval was 
obtained from the ethical committee of Wen Zhou 
Medical college (Approval Reference Number - 
4208211) and was performed in compliance with 
the guide for care and use of laboratory animals 
[13]. 
 
Hypoxic-ischemic (HI) brain injury procedure 
 
Ten-day-old pups were subjected to HI brain 
injury as described by Shen et al [14]. The left 
common carotid artery was ligated under 
anesthesia with 3 % isoflurane. Following 
recovery period of 90 min, the pups were placed 
in a humidified chamber containing atmosphere 
of 8 % O2/92 % N2 for a period of 2.5 h and were 
then returned to their respective cages. 
 
Measurement of brain infarction 
 
Following 24 h of HI injury, the rat pups were 
sacrificed by decapitation and brain tissues were 
immediately dissected out and 1 mm coronal 
slices were immersed in a PBS solution 
containing 2 % triphenyltetrazoliumchloride 
(TTC) at 37 °C for 25 min. The live/dead cells 
were determined based on the uptake of TTC. 
Live cells take up TTC where it is converted to 
red colour in live mitochondria. The viable tissues 
appear brick-red, and non-viable/infarcted tissue 
can be identified by the absence of red colour 
(white). The tissues were further analysed for 
infarct size and volume using NIH Image J 
imaging applications as described by Williams et 
al [15]. 
 
Histological analysis by cresyl violet staining 
 
Histologic studies were performed 48 h after HI 
insult. The brain tissues were fixed in 4 % 
paraformaldehyde and embedded in paraffin. 
Sections (4-5 μm) were mounted on glass cover 
slides and were deparaffinized and rinsed with 
distilled water and incubated for 15 min in 1 % 
cresyl violet solution. After incubation, the 
sections were rinsed in water and destained with 
1 % acetic acid solution and finally dehydrated by 
rinsing with ethanol. The slides were rinsed 
thoroughly and observed under microscopy, 
photographed and analysed [16]. 
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Evaluation of neuro-apoptosis 
 
Neuro-apoptosis was evaluated by immuno-
histochemical staining for activated caspase-3 
and Fluoro-Jade C staining. The analysis was 
performed as described previously [17]. The 
brain tissue sections were embedded in paraffin 
(5 µm) and incubated overnight at 4 °C with anti-
cleaved caspase-3 primary antibody (1:200; 
monoclonal antibody, Cell Signalling Technology, 
Beverly, MA, USA). The tissue sections were 
further incubated with secondary antibody 
(1:200, Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) for 40 min. The sections were 
then incubated with avidin-biotinylated 
peroxidase complex (Vectostain ABC-Kit, Vector 
Lab, Burlingame, CA, USA) for 40 min and 
stained with diaminobenzidine (DAB, Vector 
Laboratories, Burlingame, CA, USA). The 
immune-positive cells in the various sections of 
the brain tissue - hippocampal CA1, CA3 and 
dentate gyrus (DG) were analyzed using NIS-
Elements BR imaging processing and analysis 
software (Nikon Corporation, Japan).  
 
For fluoro-Jade C staining, the tissue sections of 
60 µm thickness were stained with Fluoro-Jade 
C, a marker very specific for neurodegeneration. 
The apoptotic cell counts were recorded as 
Fluoro-Jade positive cells using Nikon Eclipse 
80i microscope under 20 x magnification. 
 
Western blot analysis 
 
The cytosolic and nuclear fractions were 
prepared and subjected to western blotting [18]. 
The samples were homogenized in lysis buffer(5 
M NaCl, ,10 % Nonidet P-40, 1 M HEPES, 0.1 M 
EGTA, 0.5 M  EDTA, 0.1 M  phenylmethyl-
sulfonyl fluoride, 1 M sodium fluoride, 0.2 M 
sodium orthovanadate,  2 µg/mL aprotinin, and 2 
µg/mL leupeptin) and centrifuged at 20,000 g for 
15 min at 4 °C. The supernatant was collected 
and protein content was determined using 
Beyotime protein assay kit (Beyotime Institute of 
Biotechnology, Nanjing, China). Equal amounts 
of protein (40 µg) were separated by 
electrophoresis on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gels (10 %) 
and then transferred to polyvinylidene fluoride 
membrane (Millipore, Billerica, USA). The 
membrane was blocked with 5 % non-fat dry milk 
in tris-buffered saline containing 0.05 % Tween-
20 (TBST) buffer and incubated overnight at 4 °C 
with primary antibodies. Membranes were 
washed thrice with TBST buffer and further 
incubated with secondary antibodies coupled to 
horseradish peroxidase (1:1000 dilution, Santa 
Cruz Biotechnology) for 2 h at room temperature. 
The immunoreactive bands were detected by 
enhanced chemiluminescence system according 
to the manufacturer’s protocol (Millipore, 
Billerica, USA). The signals were analysed by 
scanning densitometry (Quantity One Software 
Bio-Rad Laboratories, Hercules, CA, USA). The 





Expression of the genes coding for inflammatory 
mediators in the cortex at 24 h following H/I 
induction was analyzed. The mRNA levels of 
TNF-α, iNOS, COX-2, IL-1α, IL-1β and IL-6 and 
were determined. Total RNA was isolated from 
lysed cells using the RNeasy kit according to the 
manufacturer’s instructions (Qiagen, Valencia, 
CA). RT-PCR was performed as described by 
Shen et al. [14]. Total RNA was amplified by 












TTC and, reverse- TCTGCTTGGTGGTTTGCTA 
CGAC and GAPDH forward –CCAGCCTCGT 





The results are presented as mean ± SD (n = 3 
or 6). Data were analysed by one-way analysis of 
variance (ANOVA) followed by post-hoc analysis 
using Duncan’s Multiple Range Test. The data 
obtained were analysed using SPSS software 
(version 22.0).Differences were considered 




Ellagic acid pretreatment reduced brain 
infarct  
 
Extensive infarction was seen in the cerebral 
cortical and sub-cortical areas in rats subjected 
to HI (Fig. 1). Rats pre-treated with ellagic acid 
(10, 20 or 40 mg/kg) had significantly (p < 0.05) 
reduced infarct volumes in comparison to HI 
control. Further a striking rise in infract weight 
was observed in HI induced rats pups. Ellagic 
acid treatment remarkably reduced the infarct 
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weight. 40 mg dose brought more significant 
reductions than lower doses, suggesting dose-
dependent reduction in infarct weight and 
volume. 
 
Effect of ellagic acid on brain tissue histology 
following HI  
 
Cresyl violet staining revealed the morphology of 
normal viable cells as round and pale stained 
nuclei throughout the tissue sections of cerebral 
cortex, hippocampus and striatum (Fig. 2). 
Higher numbers of cells under apoptosis were 
observed as shrunken cells with pyknotic nuclei. 
Further, large areas of tissue loss were also 
observed in the ipsilateral cerebral cortex, 
striatum and hippocampus of HI control animals. 
Ellagic acid treatment decreased the apoptotic 
cell counts and also reduced the extent of tissue 
damage. Hippocampus had more injury when 
compared to the cortex and striatum. While 10 
mg ellagic acid did reduce the degree of brain 
injury, 20 and 40 mg doses were more effective. 
Ellagic acid (40 mg) reduced the tissue loss to 
nearly 13.1 % in the hippocampus as against 




Figure 1: Effect of Ellagic acid on infarct weight and volume following HI. The results are represented as mean ± 
SD(n = 6);‘a’ represents statistical significance at p < 0.05 compared to control; and ‘b’ to ‘f’ represent significant 





Figure 2: Effect of Ellagic acid on the intensive tissue loss following HI. Significant (p < 0.05) reduction in brain-
loss following ellagic acid treatment was observed post-HI-injury with maximum protection at 40 mg dose. Values 
are represented as mean ± SD, n = 6. A represents statistical significance at p < 0.05 compared against control 
and b-f represents significant difference (p < 0.05) between mean values of different experimental groups as 
determined by one-way ANOVA followed by DMRT analysis 
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Ellagic acid markedly inhibits neuronal 
apoptosis following HI-induced brain injury 
 
Activation of caspase-3 was considered as a 
measure of apoptosis. Caspase-3 positive cells 
were detected in CA1 and CA3 areas of 
hippocampus and in the DG. HI resulted in a 
striking (p < 0.05) increase in number of 
caspase-3 positive cell counts (Fig. 3). The 
expression levels of caspase-3 as determined by 
western blot analysis indicated significant 
increase (p < 0.05) following HI-injury (Fig 4). 
Ellagic acid (10, 20 or 40 mg) pre-treatment 
significantly (p < 0.05) inhibited caspase-3 
activation as compared to HI control pups. 
Immuno-reactivity towards cleaved caspase-3 in 
the brain tissues exhibited a dramatically 
reduced number of caspase-3-positive cells in 
the hippocampus of animals administered ellagic 
acid. The decrease in the expression of caspase-
3 and in the number of apoptotic cell counts was 
observed to be dose-dependent. Furthermore, 
increased expression level of caspases-8 and 9 
in HI was significantly reduced on ellagic acid 
treatment (Fig. 4). Also the Fluoro-Jade C 
positive cells (p < 0.03) were found to be lowered 






Figure 3:  Effect of Ellagic acid on the intensive apoptotic neurodegeneration due to HI. Ellagic acid caused 
significant decrease in the expressions of activated caspase-3 expressions (A) and apoptotic cell counts 
(B)Values are represented as mean ± SD, n = 6. a represents statistical significance at p< 0.05 compared against 
control and b-f represents significant difference (p< 0.05) between mean values as determined by one-way 
ANOVA followed by DMRT analysis 
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Effect of ellagic acid on apoptotic pathway 
proteins 
 
The expression of pro-apoptotic (Bad and Bax) 
and anti-apoptotic proteins (Bcl-2 and Bcl-xL) 
were assessed following HI insult. Bcl-2 family 
proteins are important regulators of apoptosis. In 
our study, HI-insult resulted in multi-fold increase 
in expression of Bad and Bax proteins with 
significant decrease (p< 0.05) in Bcl-2 and Bcl-xL 
expressions. Ellagic acid administration caused a 
tremendous decline in the expression levels of 
pro-apoptotic proteins while it enhanced survival 
proteins- Bcl-xL and Bcl-2 (Fig. 4). The 
expression of proteins were in line with the 






Figure 4: Effect of Ellagic acid on the expressions of apoptotic pathway proteins. Ellagic acid markedly down-
regulated the expressions of caspases, Bad and Bax while elevating the expressions of Bcl-2 and Bcl-xL (A) (L1-
Control; L2-HI; L3-10 mg Ellagic acid +HI; L4-20 mg Ellagic acid +HI; L5-40 mg Ellagic acid +HI); (B) Relative 
expressions. Values are represented as mean ± SD, n = 6. a represents statistical significance at p < 0.05 
compared against control and b-f represents significant difference (p < 0.05) between mean values as 
determined by one-way ANOVA followed by DMRT analysis 
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Ellagic acid modulated the expression of 
MAPK proteins 
 
The results reveal a significantly (p < 0.05) raised 
levels of JNK, p-JNK, p-38 and p-p-38. Not much 
rise in ERK1/2 expressions were observed. 
Ellagic acid strikingly down-regulated the 
expressions of JNK and p38MAPK (Fig. 5). While 
significant suppression of JNK was observed, 
ellagic acid brought about only a small decrease 
in the expression of ERK1/2. The inhibitory 
effects of ellagic acid observed were dose-
dependent. 
 
Influence of ellagic acid on expression of 
inflammatory mediators 
 
A striking increase in the expression of p65 NF-
κB and p-IK-Bα on HI-injury was observed. 
Interestingly, ellagic acid administration caused a 
remarkable decrease in NF-κB and p-IK-Bα (Fig. 
6) and also in the mRNA levels of TNF-α, COX-




Figure 5: Effect of Ellagic acid on the expressions of MAPK pathway proteins. (A) L1-Control; L2-HI; L3-10 mg 
Ellagic acid +HI; L4-20 mg Ellagic acid +HI; L5-40 mg Ellagic acid +HI (B). Values are represented as mean ± 
SD, n = 6. a represents statistical significance at p< 0.05 compared against control and b-f represents significant 
difference (p< 0.05) between mean values as determined by one-way ANOVA followed by DMRT analysis 
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Figure 6: Effect of Ellagic acid on the expressions NF-κB and IK-Bα following HI-injury. Ellagic acid pre-treatment 
caused striking decreases in the activated forms of NF-κB and IK-Bα (A). L1-Control; L2-HI; L3-10 mg Ellagic 
acid +HI; L4-20 mg Ellagic acid +HI; L5-40 mg Ellagic acid +HI (B). Values are represented as mean ± SD, n = 6. 
a represents statistical significance at p < 0.05 compared against control and b-f represents significant difference 




Figure 7: Effect of ellagic acid on the expressions 
inflammatory mediators following HI-injury. (L1-
Control; L2-HI; L3-10 mg ellagic acid +HI; L4-20 mg 
ellagic acid +HI; L5-40 mg ellagic acid +HI). Ellagic 
acid potentially inhibited the expressions of 
inflammatory mediators post-HI-injury. Significantly (p 
< 0.05) enhanced expressions of the inflammatory 
mediators following HI injury were effectively down-
regulated by Ellagic acid in a dose-dependent manner. 
DISCUSSION 
 
Perinatal HI brain injury is a common cause of 
mortality and neurological deficits in infants and 
children [19]. The pathological process that may 
possibly contribute to neuronal death and 
dysfunction includes inflammatory responses, 
apoptosis, excitotoxicity and oxidative stress [20]. 
Unfortunately, the therapeutic interventions are 
limited. 
 
In this study, ellagic acid (10, 20 or 40 mg/kg) 
administered for a week significantly protected 
the neonatal brain from HI injury. The infarct size 
and volume were reduced. Studies have reported 
that neonatal brain cells exhibit features of 
apoptosis following HI insult [21].Apoptosis has 
been reported as a typical mechanism of cell 
death in the developing brain. Cresyl violet and 
Fluoro-Jade C staining revealed enhanced 
apoptosis that was significantly reduced by 
ellagic acid. Further, it has been reported that 
both caspase-dependent [22] and caspase-
independent [23] pathways are activated in brain 
injury after HI. Caspase-3 activation is 
considered as a reliable marker of the apoptotic 
neuronal cell death in HI brain injury [24]. 
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Western blot analysis revealed enhanced 
expression of caspases-3, 8 and 9 in the brain 
tissues of neonatal rats following HI. The 
activation of caspases 8 and 9 eventually leads 
to the activation of caspase-3 [25]. Thus 
increases in caspase-8 and 9 expression reflects 
the expression of caspase-3.The increase was in 
line with the apoptotic cell counts observed, 
indicating the activation of the caspase cascades 
that were effectively down-regulated by ellagic 
acid. 
 
Neuro-inflammation is implicated in hypoxic 
injuries of neonatal brain [26]. Inflammatory 
cytokines- TNF-α and IL-1β, along with nitric 
oxide (NO) produced by activated microglial cells 
lead to neuronal injury [27].Also targeting MAPK 
signalling pathways in cerebral injury is valuable 
in treatment as these pathways are associated 
with apoptotic signalling as well [28]. Studies 
have reported that inflammatory mediators 
produced in cerebral HI injury activate MAPK 
signalling cascades [29,30]. Our results 
demonstrate significant activation of JNK, 
ERK1/2 and p38 suggesting activation of MAPK 
cascades. Strikingly reduced levels of JNK, p-
JNK, p38and p-38 were observed on ellagic acid 
pre-treatment, only negligible inhibitory effects 
were noticed on ERK1/2 and p-ERK1/2. Earlier 
researches have demonstrated that activated 
JNK and p38 MAPKs chiefly function to arbitrate 
cellular stress in cerebral ischemic injury by 
regulating the activities of intracellular enzymes 
and transcription factors, associated with cell 
survival and apoptosis [29]. Thus, suppression of 
JNK and p-38 MAPK and inflammatory mediators 
could have possibly contributed to the decrease 
in neuronal apoptosis.  
 
HI injury resulted in a drastic increase in the 
expression of NF-κB p65 and p-IκBα. NF-κB 
regulates genes involved in inflammation and 
stress responses [31]. Under pathological 
conditions, IκB is phosphorylated resulting in 
active NF-κB [32] and gets translocated to the 
nucleus where it regulates target gene 
expression. An increase in phosphorylated NF-
κB in hypoxic microglia of neonatal rats has been 
reported previously [33].  Significant increase in 
the expression levels of IL-6, COX-2, NF-κB and 
iNOS were also observed. Marked suppression 
of NF-κB p65, IL -1β, IL-1α and p-IκBα suggests 
the potent anti-inflammatory efficiency of ellagic 
acid. Enhanced p65NF-κB expression observed 
was in line with the expression of TNF-α, COX-2, 
IL-1α, IL-1β, IL-6 and iNOS following HI.  Recent 
studies reported that the functions of TNF-α and 
IL-1β were mediated through caspase cascades 
and iNOS [34]. The down-regulation of 
inflammatory mediators thus curbs inflammation, 
suggesting anti-inflammatory effects as one of 





Ellagic acid reduces brain infarct size and 
apoptosis of brain cells through mechanisms 
such as down-regulation of apoptotic pathway 
proteins, suppression of MAPK cascades and 
expression of inflammatory mediators. MAPK 
cascades are critically associated with cell 
survival and apoptosis. Furthermore, neuro-
inflammation adsorbed in HI potentially 
contributes to apoptosis. Down-regulation of 
MAPKs and inflammatory protein expression by 
ellagic acid reveals its protective effects in HI.  
The results suggest that ellagic acid may be 
useful in therapeutic strategies for brain injury. 
However, the potential neuroprotective effects of 
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